# Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

> **NCT01948141** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 6 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Squamous Cell Lung Cancer
- Stage III Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** nintedanib

## Key facts

- **NCT ID:** NCT01948141
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-30
- **Primary completion:** 2016-08-16
- **Final completion:** 2016-08-16
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-06-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01948141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01948141, "Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01948141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*